Positron Emission Tomography–Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer

Yuan, 2007, A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer, Am J Clin Oncol, 30, 239, 10.1097/01.coc.0000256691.27796.24 Bradley, 2015, Lancet Oncol, 16, 187, 10.1016/S1470-2045(14)71207-0 Fischer, 2009, Preoperative staging of lung cancer with combined PET-CT, N Engl J Med, 361, 32, 10.1056/NEJMoa0900043 Ohri, 2015, Pretreatment FDG-PET metrics in stage III non-small cell lung cancer: ACRIN 6668/RTOG 0235, J Natl Cancer Inst, 107, 10.1093/jnci/djv004 Ohri, 2015, Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer, Lung Cancer, 87, 23, 10.1016/j.lungcan.2014.10.016 Chun, 2017, Impact of intensity-modulated radiation therapy technique for locally advanced non–small-cell lung cancer: A secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial, J Clin Oncol, 35, 56, 10.1200/JCO.2016.69.1378 Machtay, 2012, Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the Radiation Therapy Oncology Group, Int J Radiat Oncol Biol Phys, 82, 425, 10.1016/j.ijrobp.2010.09.004 Fowler, 2000, Non-small cell lung tumors repopulate rapidly during radiation therapy, Int J Radiat Oncol Biol Phys, 46, 516, 10.1016/S0360-3016(99)00364-8 Machtay, 2013, Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: Results of the ACRIN 6668/RTOG 0235 trial, J Clin Oncol, 31, 3823, 10.1200/JCO.2012.47.5947 Ramroth, 2016, Dose and fractionation in radiation therapy of curative intent for non-small cell lung cancer: Meta-analysis of randomized trials, Int J Radiat Oncol Biol Phys, 96, 736, 10.1016/j.ijrobp.2016.07.022 Yamoah, 2015, Radiation therapy intensification for solid tumors: A systematic review of randomized trials, Int J Radiat Oncol Biol Phys, 93, 737, 10.1016/j.ijrobp.2015.07.2284 Feddock, 2013, Stereotactic body radiation therapy can be used safely to boost residual disease in locally advanced non-small cell lung cancer: A prospective study, Int J Radiat Oncol Biol Phys, 85, 1325, 10.1016/j.ijrobp.2012.11.011 Albain, 2009, Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: A phase III randomised controlled trial, Lancet, 374, 379, 10.1016/S0140-6736(09)60737-6 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774 Ohri, 2017, 18 F-fluorodeoxyglucose/positron emission tomography predicts patterns of failure after definitive chemoradiation therapy for locally advanced non-small cell lung cancer, Int J Ratiat Oncol Biol Phys, 97, 372, 10.1016/j.ijrobp.2016.10.031 Palma, 2013, Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis, Int J Radiat Oncol Biol Phys, 87, 690, 10.1016/j.ijrobp.2013.07.029 Wang, 2017, Cardiac toxicity after radiotherapy for stage III non-small-cell lung cancer: Pooled analysis of dose-escalation trials delivering 70 to 90 Gy, J Clin Oncol, 35, 1387, 10.1200/JCO.2016.70.0229 Dess, 2017, Cardiac events after radiation therapy: Combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer, J Clin Oncol, 35, 1395, 10.1200/JCO.2016.71.6142 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Tang, 2014, Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes, Int J Radiat Oncol Biol Phys, 89, 1084, 10.1016/j.ijrobp.2014.04.025 Nishino, 2015, Anti-PD-1-related pneumonitis during cancer immunotherapy, N Engl J Med, 373, 288, 10.1056/NEJMc1505197 Urbanic, 2015, Phase 1 study of accelerated hypofractionated radiation therapy with concurrent chemotherapy for stage III non-small cell lung cancer: CALGB 31102 (Alliance), Int J Radiat Oncol Biol Phys, 93, S86, 10.1016/j.ijrobp.2015.07.207 Machtay, 2005, Pilot study of accelerated radiotherapy with concurrent chemotherapy for stage III non-small cell lung cancer, Semin Oncol, 32, S9, 10.1053/j.seminoncol.2005.03.004 van Elmpt, 2012, The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer, Radiother Oncol, 104, 67, 10.1016/j.radonc.2012.03.005 Kong, 2017, Effect of midtreatment PET/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: A phase 2 clinical trial, JAMA Oncol, 3, 1358, 10.1001/jamaoncol.2017.0982 Werner-Wasik, 2012, What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom, Int J Radiat Oncol Biol Phys, 82, 1164, 10.1016/j.ijrobp.2010.12.055